• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Insulet COO announces intent to retire

December 15, 2022 By Sean Whooley

Insulet EVP COO Charles Chuck Alpuche
Charles Alpuche. [Image from Insulet’s website]
Insulet (Nasdaq:PODD) issued an SEC filing confirming that Charles Alpuche, executive vice president and chief operating officer, intends to retire.

Alpuche informed the company of his decision to retire on Dec. 13. His retirement takes effect on Dec. 31, 2022.

The Acton, Massachusetts-based automated insulin delivery technology developer promoted Prem Singh as a result. Singh currently serves as VP and head of global supply chain operations at Insulet. He takes over as SVP, global operations, effective Jan. 1, 2023.

According to a news release, Alpuche agreed to remain with Insulet from Jan. 1, 2023, through April 1, 2023. He intends to assist with the transition of responsibilities to Singh.

This marks the second executive departure at Insulet this year. In May, CEO Shacey Petrovic stepped down due to personal reasons. Former ResMed executive Jim Hollingshead took over the corner office.

In the meantime, Insulet made major strides in 2022 around its next-generation Omnipod 5. It became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January. Since, it received both FDA approval and CE mark approval for children two years old and up.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel Tagged With: Insulet, Personnel Moves

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS